ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas
OncLive,
Stephen Bagley, MD, MSCE Following encouraging early efficacy signals seen in patients with H3K27M-mutated diffuse midline…
Stephen Bagley, MD, MSCE Following encouraging early efficacy signals seen in patients with H3K27M-mutated diffuse midline…
An international team of investigators has identified a drug candidate that nearly doubles survival rates for patients with…
Scientists have discovered great potential in an up-and-coming drug that targets an aggressive form of brain cancer.